NCT06887452|RecruitingDMC
Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout
Pham-UP
Loading search results
Pham-UP
Sponsor study identifier
Secondary identifiers
OTHER_GRANT · VA CSR&D
interventional
310
1 country
5
Study Start
October 1, 2026
Actual (reported)Primary Completion
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 13, 2025
Actual (reported)March 20, 2025
Actual (reported)October 1, 2026
Actual (reported)October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
March 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
flare occurrence
The occurrence of two or more flares during year 2.
during year two
serum urate at goal
Achievement of serum urate \<6 milligrams per deciliter (mg/dL) at end of year one.
at end of year one
Veterans RAND 12 (VR-12)
Baseline visit, Months 6, 12, 18, and 24
Patient Reported Outcomes Measurement Information System (PROMIS)
Baseline visit, Months 6, 12, 18, and 24
Gout-related patient global assessment
Baseline visit, Months 6, 12, 18, and 24
Veterans will participate in regular telehealth visits with study pharmacists. Serum urate lab tests will be ordered during dose escalation phase of gout treatment.
Veterans will receive standard care from their primary care provider for the management of their gout.
Pharmacist will conduct regular telehealth visits with Veterans during dose escalation phase of gout treatment
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
Omaha, Nebraska, 68105-1850, United States
VA Portland Health Care System, Portland, OR
Portland, Oregon, 97207-2964, United States
Ted R. Mikuls
Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE
First Submitted
March 13, 2025
First Posted
March 20, 2025
Study Start
October 1, 2026
Actual (reported)Primary Completion
The Remote Monitoring of Gout Feasibility Study in Primary Care
Contact the study team to confirm eligibility.
Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Philadelphia, Pennsylvania, 19104-4551, United States
VA Salt Lake City Health Care System, Salt Lake City, UT
Salt Lake City, Utah, 84148-0001, United States
VA Puget Sound Health Care System Seattle Division, Seattle, WA
Seattle, Washington, 98108-1532, United States
October 1, 2029
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
March 30, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 21, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: